Literature DB >> 29251734

Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.

Nicolas Piton1,2, Philippe Ruminy2, Claire Gravet1, Vinciane Marchand2, Élodie Colasse1, Aude Lamy1, Cécile Le Naoures Mear3, Fréderic Bibeau3, Florent Marguet1, Florian Guisier4, Mathieu Salaün4, Luc Thiberville4, Fabrice Jardin3, Jean-Christophe Sabourin1,2.   

Abstract

Detection of anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), and rearranged during transfection (RET) gene rearrangements in lung adenocarcinoma is usually performed by immunohistochemistry (IHC) screening followed by fluorescence in situ hybridization (FISH), which is an expensive and difficult technique. Ligation-dependent reverse transcription polymerase chain reaction (RT-PCR) multiplex technique can detect gene rearrangements using probes specifically hybridized to either side of the break point. PCR products are then sequenced by pyrosequencing or high throughput sequencing in order to identify the two genes involved. The reagent cost is <15 dollars per patient and results are available in 2 days. We have developed a 47-probe LD-RT-PCR kit especially for lung adenocarcinomas. Thirty-nine lung adenocarcinomas were studied: 24 ALK+, 14 ROS1+, and 1 RET+. ALK+ and ROS1+ were IHC+ (D5F3 Ventana for ALK and D4D6 Cell Signaling Technology for ROS1) and all cases were FISH+ (Vysis ALK Breakapart Probe Abbott for ALK, Zytolight SPEC ROS1 Dualcolor Breakapart Probe for ROS1 and Zytolight SPEC RET Dual Color Breakapart for RET); 14 wild type samples were included as negative controls. Using LD-RT-PCR, 15 rearrangements (63%) were detected in the ALK cases (gene partner: EML4 in all cases), 9 rearrangements (64%) in the ROS1 cases (gene partners: CD74 in 8 cases and SLC34A2 in 1 case) and 1 (100%) in the single RET case (gene partner: KIF5B). No rearrangement was found in the 14 negative control cases. Negative cases using LD-RT-PCR could be explained by the fact that some partner genes were not included in our assay and therefore could not be detected. Because it is an affordable, fast, and very simple technique, we propose using LD-RT-PCR when ALK immunostaining is positive. For LD-RT-PCR-negative cases, samples should then be analyzed by FISH.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29251734     DOI: 10.1038/labinvest.2017.124

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  16 in total

1.  Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Authors:  Julien Mazières; Gérard Zalcman; Lucio Crinò; Pamela Biondani; Fabrice Barlesi; Thomas Filleron; Anne-Marie C Dingemans; Hervé Léna; Isabelle Monnet; Sacha I Rothschild; Federico Cappuzzo; Benjamin Besse; Luc Thiberville; Damien Rouvière; Rafal Dziadziuszko; Egbert F Smit; Jurgen Wolf; Christian Spirig; Nicolas Pecuchet; Frauke Leenders; Johannes M Heuckmann; Joachim Diebold; Julie D Milia; Roman K Thomas; Oliver Gautschi
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.

Authors:  Tatsushi Kodama; Toshiyuki Tsukaguchi; Yasuko Satoh; Miyuki Yoshida; Yoshiaki Watanabe; Osamu Kondoh; Hiroshi Sakamoto
Journal:  Mol Cancer Ther       Date:  2014-10-27       Impact factor: 6.261

3.  Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study.

Authors:  Sylvain Mareschal; Philippe Ruminy; Cristina Bagacean; Vinciane Marchand; Marie Cornic; Jean-Philippe Jais; Martin Figeac; Jean-Michel Picquenot; Thierry Jo Molina; Thierry Fest; Gilles Salles; Corinne Haioun; Karen Leroy; Hervé Tilly; Fabrice Jardin
Journal:  J Mol Diagn       Date:  2015-04-09       Impact factor: 5.568

4.  French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.

Authors:  Sylvie Lantuejoul; Isabelle Rouquette; Hélène Blons; Nolwenn Le Stang; Marius Ilie; Hugues Begueret; Valerie Grégoire; Paul Hofman; Audrey Gros; Stephane Garcia; Nathalie Monhoven; Mojgan Devouassoux-Shisheboran; Audrey Mansuet-Lupo; Françoise Thivolet; Martine Antoine; Jean-Michel Vignaud; Frederique Penault-Llorca; Françoise Galateau-Sallé; Anne McLeer-Florin
Journal:  Eur Respir J       Date:  2015-04-30       Impact factor: 16.671

5.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 6.  Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Authors:  Justin F Gainor; Alice T Shaw
Journal:  Oncologist       Date:  2013-06-28

7.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

8.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

9.  KIF5B-RET fusions in lung adenocarcinoma.

Authors:  Takashi Kohno; Hitoshi Ichikawa; Yasushi Totoki; Kazuki Yasuda; Masaki Hiramoto; Takao Nammo; Hiromi Sakamoto; Koji Tsuta; Koh Furuta; Yoko Shimada; Reika Iwakawa; Hideaki Ogiwara; Takahiro Oike; Masato Enari; Aaron J Schetter; Hirokazu Okayama; Aage Haugen; Vidar Skaug; Suenori Chiku; Itaru Yamanaka; Yasuhito Arai; Shun-Ichi Watanabe; Ikuo Sekine; Seishi Ogawa; Curtis C Harris; Hitoshi Tsuda; Teruhiko Yoshida; Jun Yokota; Tatsuhiro Shibata
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

10.  A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.

Authors:  John Le Quesne; Manisha Maurya; Slaveya G Yancheva; Mary O'Brien; Sanjay Popat; Andrew C Wotherspoon; David Gonzalez de Castro; Andrew G Nicholson
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

View more
  7 in total

1.  Rapid detection and genotyping of ALK fusion variants by adapter multiplex PCR and high-resolution melting analysis.

Authors:  Mei Li; Shen Lu; Xu Sun
Journal:  Lab Invest       Date:  2019-10-22       Impact factor: 5.662

2.  An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology.

Authors:  Nicolas Piton; Marie-Delphine Lanic; Florent Marguet; Aude Lamy; France Blanchard; Florian Guisier; Mathieu Viennot; Mathieu Salaün; Luc Thiberville; Fabrice Jardin; Jean-Christophe Sabourin; Philippe Ruminy
Journal:  Lab Invest       Date:  2021-01-25       Impact factor: 5.662

3.  Detection of sarcoma fusions by a next-generation sequencing based-ligation-dependent multiplex RT-PCR assay.

Authors:  Marie-Delphine Lanic; François Le Loarer; Vinciane Rainville; Vincent Sater; Mathieu Viennot; Ludivine Beaussire; Pierre-Julien Viailly; Emilie Angot; Isabelle Hostein; Fabrice Jardin; Philippe Ruminy; Marick Laé
Journal:  Mod Pathol       Date:  2022-01-24       Impact factor: 7.842

4.  Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.

Authors:  Maxime Fontanilles; Florent Marguet; Philippe Ruminy; Carole Basset; Adrien Noel; Ludivine Beaussire; Mathieu Viennot; Pierre-Julien Viailly; Kevin Cassinari; Pascal Chambon; Doriane Richard; Cristina Alexandru; Isabelle Tennevet; Olivier Langlois; Frédéric Di Fiore; Annie Laquerrière; Florian Clatot; Nasrin Sarafan-Vasseur
Journal:  Acta Neuropathol Commun       Date:  2020-04-17       Impact factor: 7.801

Review 5.  Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches.

Authors:  Vincenza Ylenia Cusenza; Alessandra Bisagni; Monia Rinaldini; Chiara Cattani; Raffaele Frazzi
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

6.  The SLC34A2-ROS-HIF-1-induced up-regulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer.

Authors:  Xu Li; Junjie Xing; Hantao Wang; Enda Yu
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

7.  Co-occurrence of PML-RARA gene fusion, chromosome 8 trisomy, and FLT3 ITD mutation in a young female patient with de novo acute myeloid leukemia and early death: A CARE case report.

Authors:  Florin Tripon; George Andrei Crauciuc; Alina Bogliş; Valeriu Moldovan; Johanna Sándor-Kéri; István Jr Benedek; Adrian Pavel Trifa; Claudia Bănescu
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.